Factor XIa Inhibitor Shows No Benefit After Acute Coronary Syndrome

(MedPage Today) -- An investigational factor XIa inhibitor did not reduce the risk of recurrent cardiovascular (CV) events in patients with a recent acute coronary syndrome (ACS) event on top of antiplatelet therapy, although there was no increase...